A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program

NCT04657016 · Completed

Last updated 2026-05-28

This clinical trial is testing the medication tirzepatide in adults who are overweight or have obesity after they have completed a lifestyle-based weight loss program.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 579 people

Who can join Ages 18+ · all sexes

Timeline Started 2021-03 · est. completion 2023-05

Where 65 sites · Argentina, Brazil, Puerto Rico, United States

What this study is testing ClinicalTrials.gov NCT04657016 ↗

Description as written by the study sponsor.

This is a study of tirzepatide in participants with obesity. The purpose of this study is to learn more about how tirzepatide maintains body weight or adds to weight loss after an intensive lifestyle modification program. The study will last about 2 years (29 visits).

Treatments tested

Tirzepatide also known as LY3298176 Drug

Administered SC
Placebo Other

Administered SC

Main thing measured	Percent Change From Baseline in Body Weight
Sponsor	Eli Lilly and Company
Conditions studied	Obesity, Overweight
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04657016 ↗